doi:10.1177/2050313X251388724 Frontiers in Clinical Diabetes and Healthcare
The FDA approved a different formulation of Semaglutide GLP-1, marketed as Wegovy, which is explicitly designed for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition, such as high blood pressure or type 2 diabetes
But with rapid weight loss, many people begin to notice new concerns like loose skin, fatigue, and decreased energy
Table of Contents What Are Sulphur Burps and Why Do GLP-1 Medications Cause Them
However, they are not a treatment for side effects, and severe or persistent symptoms require medical evaluation to rule out serious complications
This starting dose is intended for treatment initiation to help your body adjust and is not effective for blood sugar control